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economic burden of stroke was estimated from a societal perspective with an 
incidence approach.Data were collected from clinical registries and 100 patients 
were included. In the cost calculations, both direct and indirect costs were esti-
mated. Results: Men (78%) consumed more acute care in hospitals, than the 
women (22%). Younger patients (59%) brought a significantly higher burden on 
society compared with the older patients due to the loss of productivity and the 
increased use of resources in health care.41% of patients who have hypertension 
and 45% of patients with alcohol and smoking habits have more prone to stroke 
rather than the patients with other habits and comorbidities.56% of patients have 
the hospital stay of 5-10 days and 52% are using 4-7 medicines per day. From 
the study results ,average direct medical costs and direct nonmedical costs and 
Indirect costs were found to be 2819 ,705 and 754 rupees. In essence, majority of 
the costs for stroke care fall on the hospital,than the long-time care and informal 
care costs and productivity loss. ConClusions: The result of this study can be 
used for further development of the methods for economic analyses as well as for 
analysis of improvements and investments in health care. This aspect highlights 
the enormous importance, for our healthcare service, to invest more in preven-
tion. This cost analysis highlights the importance of clinical pharmacist to set up 
significant prevention programs on selected,high-risk population to reduce the 
economic burden of stroke, which is mostly attributable to hospital and inpatient 
rehabilitation costs immediately after the acute episode.
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objeCtives: To review the direct patient-level costs of selected cardiovascular 
events (CVEs): unstable angina, myocardial infarction (MI), cardiac revasculariza-
tion, heart failure, ischemic stroke, acute coronary syndrome in Europe. Methods: 
A systematic literature review was conducted for the period between January 
2000 and March 2015. MEDLINE, EMBASE, ECONLIT, and NHS Economic Evaluation 
Database, conference abstracts from the American Heart Association, American 
College of Cardiology, European Society of Cardiology, European Atherosclerosis 
Society, International Society of the Pharmacoeconomics and Outcomes Research 
and relevant reference lists were searched to identify published articles reporting 
direct costs of one or more CVEs (angina, myocardial infarction, cardiac revas-
cularization, heart failure, ischemic stroke, acute coronary syndrome) in Europe 
(United Kingdom, Germany, Spain, France, Italy, Denmark, Finland, Iceland, 
Norway, Sweden, Belgium, Switzerland, The Netherlands). Two reviewers indepen-
dently assessed studies against inclusion criteria and abstracted cost estimates; 
discrepancies were resolved through discussion or by third reviewer. Studies were 
included if they reported patient-level direct medical costs of one or more CVE(s) 
from a primary economic analysis or cost-effectiveness model among adults with 
identified dyslipidemia or elevated Low Density Lipoprotein-Cholesterol. Costs as 
reported in each study were inflated to 2015 values. Results: Forty-eight studies 
were included for abstraction. Cost estimates for at least one event were found 
in twelve of the thirteen specified countries listed in the search strategy. Annual 
costs of care were highest for stroke (€ 958-€ 10,334), revascularization procedures 
(€ 211-€ 12,383) and MI (€ 558-€ 17,262). The highest cost acute events were revas-
cularization procedures, specifically CABG (€ 10,814- € 25,587), and ischemic stroke 
(€ 3,686-€ 7,978); angina (€ 935-€ 5,214) and heart failure (€ 1,106-€ 4,905) acute costs 
were relatively lower than other conditions. ConClusions: The findings of this 
study highlight the wide variation in the sources and populations used to populate 
economic models in the literature and the substantial costs of CVEs despite event 
type or country of origin.
PCV81
eStimating tHe BurDen Of DiaBeteS tO tHe frenCH natiOnaL HeaLtH 
inSuranCe
Aguade A1, De Lagasnerie G1, Denis P1, Gastaldi-Menager C1, Fagot-Campagna A1,  
Gissot C2, Polton D2
1CNAMTS (National Health Insurance), Paris Cedex 20, France, 2CNAMTS (National Health 
Insurance), paris cedex 20, France
objeCtives: The aim is to assess for 2012 the direct and non-directly cost of dia-
betes from a public payer perspective using a new (bottom-up) method and the 
French health insurance medico-administrative database (SNIIRAM). Methods: 
Using information about 60 millions of individuals from the general scheme insur-
ance database (86% of the 69 million individuals insured by all French insurance 
schemes,), we identified people who received care for diabetes if they had an 
ICD-10 diagnosis for diabetes as a long-term chronic disease or at least 3 annual 
reimbursements for anti-diabetic drugs. Costs of all reimbursed expenditures (out-
patient/inpatient care, disability/sickness benefits) were extracted per individual. 
To estimate the burden of diabetes, we identified expenditure items which were 
directly attributable to diabetes (anti-diabetic drugs, medical devices, hospitaliza-
tion with an ICD diabetes code). For other expenditures, we used an incremental 
approach and also econometric model by estimating the additional cost due to 
diabetes (by age and gender) between the diabetic and the non-diabetic popula-
tion. Results: Among 69 million individuals insured by all insurance schemes, 3.3 
million (5%) had diabetes. The overall diabetic population expenditure accounted for 
22 billion, 15% (of the total expenditures reimbursed by the national health insur-
ance). Overall, 11.4 billion (52%) euros were considered as related to diabetes care. 
Reimbursements directly attributable to diabetes accounted for 2.6 billion (23% of 
the 11.4 billion euros) and other costs, mostly related to complications, for 8.8 billion 
(77%). Inpatient care represented the main part of the overall cost of diabetes care 
(22%) together with drugs (20%) and medical auxiliaries (15%). ConClusions: Care 
for diabetes complications and additional treatments for diabetic people account 
for the highest part of the costs of diabetes care. The prevention of acute illness 
separate models to calculate cost of illness for each selected diseases. Medical 
resources included hospital stays, outpatient visits, ambulance service and reha-
bilitation. Results: Obesity-related and overweight-related expenses incurred by 
the state for treatment and management of patients were amounted to 10.2 billion 
rubles ($ 190.5 million) for stroke, 7.6 billion rubles ($ 141.9 million) for heart attack 
and 346.3 billion rubles ($ 6.5 billion) for diabetes mellitus. ConClusions: Obesity 
and overweight associated with significant economic burden on Russia’s health care 
system. There is a striking direct relationship between the cost of care on stroke, 
heart attack, diabetes mellitus and obesity and overweight that leading to increasing 
significant economic and social losses.
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objeCtives: The prevalence of atrial fibrillation (AF), a common form of car-
diac arrhythmia, is rapidly rising in the developed world. Though several studies 
addressed the cost of illness, recent improvements in the disease management 
may have affected per capita medical resources consumption and costs, there-
fore it is desirable to provide updated estimates. This naturalistic study aimed at 
estimating costs and resource consumption related to AF from the perspective of 
the Italian Healthcare System in a large cohort of hospitalized cases. Methods: 
Using healthcare administrative databases (HADB) of Lombardy, a region in 
Northern Italy (10 million dwellers), we identified the cohort of residents who 
underwent a first hospitalization with a diagnosis of AF between 2003 and 2009, 
after a wash-out period of 3 years. We followed them until 2010, death or emi-
gration, extracting from HADB information on hospitalizations, drug prescrip-
tions and outpatient visits with related direct costs. We estimated mean annual 
resources consumption per 100 subjects and mean annual per capita cost through 
the Bang and Tsiatis approach. Results: We recruited a cohort of 143,022 sub-
jects (49% males), with a mean age of 75 years (±12 standard deviation) and a 
mean survival time of 5 years (95% confidence interval (CI): 5.0; 5.1) from baseline. 
Mean annual per-capita expenditure was 4,008€ (95%CI: 3,981; 4,039), of which 
65.2% was absorbed by hospitalizations, 18.5% by drug prescriptions and 16.3% 
by outpatient visits. We estimated 84.7 hospital admissions, the main driver of 
costs, per 100 subjects per year (95%CI: 83.8; 85.6), of which 17.0 (95%CI: 16.8; 
17.2) with an AF diagnosis. ConClusions: In line with literature, our results 
highlighted a high burden of AF, with large per capita healthcare expenditures 
and a high number of hospitalizations. Since AF has been described as an epi-
demic, increased attention should be devoted to the management of such 
disease.
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objeCtives: To estimate direct medical costs of cardiovascular (CV) events in the 
UK: myocardial infarction (MI), ischemic stroke (IS), heart failure (HF), transient 
ischemic attack (TIA), unstable angina (UA), and revascularisation. Methods: We 
used 2006-2012 Clinical Practice Research Datalink and Hospital Episode Statistics 
data to identify individuals with their first and, if present, repeated CV-related 
hospitalisations. Patients > 18 years receiving lipid-modifying therapy within 180 
days before the CV event were followed for 36 months, death, or loss to follow 
up. Patients were classified as CV Low/Moderate Risk, CV High Risk and CV Event 
History. Baseline (12 months before first CV event), acute (first 6 months after-
ward) and long-term costs (subsequent 30 months, annualised) were estimated 
by applying 2014 UK costs to drugs, hospitalisations and visits. Incremental CV 
event-related costs were calculated as the difference from baseline, reporting means 
across all cohorts and ranking cohort-specific means. Results: There were 6,408 
patients in CV Low/Moderate Risk, 17,685 in the CV High Risk, and 5,274 in CV Event 
History cohorts. Across the three cohorts, mean incremental acute CV event costs 
for revascularisation were £5,669 (£5,468-£5,823), MI £4,277 (£3,707-4,573), IS £3638 
(£3,472-4,572), HF £2,635 (£ 2390-£3461), UA £2,229 (£2063-£2489) and TIA £1,572 
(£1441-£1814). Mean incremental long-term costs were as follows: HF £1,129 (-£37-
£2829), MI £959 (£515-£1385), IS £953 (£682-£1072), TIA £793 (£340-£1692), UA £373 
(£319-£677), and revascularisation -£221 (-£411-£599). Costs of CV Low/Moderate Risk 
cohort ranked the lowest; costs of CV Event History were the highest. Hospitalisation 
costs were the primary drivers for both periods. ConClusions: Revascularisation 
and MI are the costliest CV events. The costs are the highest in the acute phase dur-
ing the first 6 months after a CV event and generally remain higher compared with 
pre-event period. Using real-world evidence, the economic burden of CV patients 
in the UK is substantial.
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objeCtives: The recently-observed trend towards the stroke patients in raises 
the economic concerns. Cost-of-illness (COI) analysis is the main method of 
providing an overall view on the economic impact of a disease. the main objec-
tive of this study is to estimate the economic burden of stroke. Methods: The 
